Centene Shares Jump On Better Than Expected Q4 Earnings, Reaffirms FY22 Guidance
See more from Benzinga
Tenet Healthcare Clocks 40% Decline In Q4 Profit, Issues Q1 Guidance Below Consensus
Sangamo Therapeutics Shares Updated Interim Data From Fabry Disease Gene Therapy Trial
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.